Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETRARCA / FLOT6
2014-002695-86Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jan 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pertuzumab, trastuzumab, docetaxel, oxaliplatin, fluorouracil and 1 more in gastroesophageal adenocarcinoma, gastric adenocarcinoma and esophagogastric junction cancer (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: pathological complete response rate. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
gastroesophageal adenocarcinomagastric adenocarcinomaesophagogastric junction cancer
Beyond the preview
Go deeper on 2014-002695-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002695-86.